These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34870794)

  • 1. An open-label, single-arm, multi-center, phase II clinical trial of single-dose [
    Inaki A; Shiga T; Tsushima Y; Jinguji M; Wakabayashi H; Kayano D; Akatani N; Yamase T; Kunita Y; Watanabe S; Hiromasa T; Mori H; Hirata K; Watanabe S; Higuchi T; Tomonaga H; Kinuya S
    Ann Nucl Med; 2022 Mar; 36(3):267-278. PubMed ID: 34870794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of High-Specific-Activity
    Pryma DA; Chin BB; Noto RB; Dillon JS; Perkins S; Solnes L; Kostakoglu L; Serafini AN; Pampaloni MH; Jensen J; Armor T; Lin T; White T; Stambler N; Apfel S; DiPippo VA; Mahmood S; Wong V; Jimenez C
    J Nucl Med; 2019 May; 60(5):623-630. PubMed ID: 30291194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I clinical trial for [
    Wakabayashi H; Inaki A; Yoshimura K; Murayama T; Imai Y; Higuchi T; Jinguji M; Shiga T; Kinuya S
    Sci Rep; 2019 May; 9(1):7625. PubMed ID: 31110198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma.
    Jimenez C; Chin BB; Noto RB; Dillon JS; Solnes L; Stambler N; DiPippo VA; Pryma DA
    Endocr Relat Cancer; 2023 Feb; 30(2):. PubMed ID: 36472300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I clinical trial for [
    Inaki A; Yoshimura K; Murayama T; Imai Y; Kuribayashi Y; Higuchi T; Jinguji M; Shiga T; Kinuya S
    J Med Invest; 2017; 64(3.4):205-209. PubMed ID: 28954983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma.
    Noto RB; Pryma DA; Jensen J; Lin T; Stambler N; Strack T; Wong V; Goldsmith SJ
    J Clin Endocrinol Metab; 2018 Jan; 103(1):213-220. PubMed ID: 29099942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis.
    Wakabayashi N; Watanabe S; Abe T; Takenaka J; Hirata K; Kimura R; Sakamoto K; Shinohara N; Kudo K
    Ann Nucl Med; 2024 Jul; 38(7):553-562. PubMed ID: 38656630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
    Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
    J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
    Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
    Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for refractory pheochromocytoma and paraganglioma after
    Hiromasa T; Wakabayashi H; Kayano D; Inaki A; Watanabe S; Mori H; Akatani N; Yamase T; Kunita Y; Saito S; Kinuya S
    Ann Nucl Med; 2022 Jan; 36(1):61-69. PubMed ID: 34647244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
    Gonias S; Goldsby R; Matthay KK; Hawkins R; Price D; Huberty J; Damon L; Linker C; Sznewajs A; Shiboski S; Fitzgerald P
    J Clin Oncol; 2009 Sep; 27(25):4162-8. PubMed ID: 19636009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid.
    Coleman RE; Stubbs JB; Barrett JA; de la Guardia M; Lafrance N; Babich JW
    Cancer Biother Radiopharm; 2009 Aug; 24(4):469-75. PubMed ID: 19694582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.
    Gedik GK; Hoefnagel CA; Bais E; Olmos RA
    Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):725-33. PubMed ID: 18071700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.
    Thorpe MP; Kane A; Zhu J; Morse MA; Wong T; Borges-Neto S
    J Clin Endocrinol Metab; 2020 Mar; 105(3):e494-501. PubMed ID: 31614368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of [
    Takenaka J; Watanabe S; Abe T; Hirata K; Uchiyama Y; Kimura R; Shinohara N; Kudo K
    Ann Nucl Med; 2023 Jan; 37(1):10-17. PubMed ID: 36301465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
    Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
    Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear medicine therapy of pheochromocytoma and paraganglioma.
    Troncone L; Rufini V
    Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma.
    Zhang X; Wakabayashi H; Kayano D; Inaki A; Kinuya S
    Nuklearmedizin; 2022 Jun; 61(3):231-239. PubMed ID: 35668668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pharmacokinetics, safety, and efficacy of [211At] meta-astatobenzylguanidine ([211At] MABG) in patients with pheochromocytoma or paraganglioma (PPGL): A study protocol.
    Kobayakawa M; Shiga T; Takahashi K; Sugawara S; Nomura K; Hanada K; Ishizuka N; Ito H
    PLoS One; 2024; 19(5):e0303623. PubMed ID: 38805424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.